Related Experiment Video
Updated: Jul 3, 2025

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
CRISPR Manipulation of Age-Related Macular Degeneration Haplotypes in the Complement System: Potential Future
Ahmed Salman1, Michelle E McClements1, Robert E MacLaren1,2
1Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
Insights
CRISPR/Cas gene editing offers a novel approach to investigate age-related macular degeneration (AMD) by targeting complement system gene variants. This strategy could lead to new therapeutic insights for AMD, addressing the limitations of current treatments.
Area of Science:
- Ophthalmology and Genetics
- Molecular Biology and Immunology
Background:
- Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss in the elderly.
- The complement system plays a significant role in AMD pathogenesis, with specific genetic variations increasing risk.
- Current treatments for AMD are limited, highlighting a need for novel therapeutic strategies.
Purpose of the Study:
- To explore the potential of CRISPR/Cas gene editing in understanding and manipulating the complement system in AMD.
- To investigate the functional implications of AMD-related single-nucleotide polymorphisms (SNPs) in complement genes.
- To bridge the knowledge gap in targeting complement system dysregulation for AMD treatment.
Main Methods:
- Reviewing current understanding of complement system involvement in AMD.
- Examining the role of AMD-associated SNPs in complement genes (CFH, CFB, C3).
- Discussing the application of CRISPR/Cas technology for genomic manipulation of these SNPs.
Main Results:
- AMD-related SNPs in complement genes alter complement cascade activation and regulation.
- CRISPR/Cas systems provide a powerful tool to study the functional impact of these SNPs.
- Targeting AMD-related SNPs offers potential diagnostic and therapeutic implications.
Conclusions:
- CRISPR/Cas-mediated targeting of AMD-related SNPs in complement genes is a promising avenue for research.
- This approach can elucidate pathogenic mechanisms and guide the development of novel AMD therapies.
- Further research is needed to translate these findings into effective clinical treatments for AMD.
Abstract:
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the elderly in the developed world. Whilst AMD is a multifactorial disease, the involvement of the complement system in its pathology is well documented, with single-nucleotide polymorphisms (SNPs) in different complement genes representing an increased risk factor. With several complement inhibitors explored in clinical trials showing limited success, patients with AMD are still without a reliable treatment option. This indicates that there is still a gap of knowledge in the functional implications and manipulation of the complement system in AMD, hindering the progress towards translational treatments. Since the discovery of the CRISPR/Cas system and its development into a powerful genome engineering tool, the field of molecular biology has been revolutionised. Genetic variants in the complement system have long been associated with an increased risk of AMD, and a variety of haplotypes have been identified to be predisposing/protective, with variation in complement genes believed to be the trigger for dysregulation of the cascade leading to inflammation. AMD-haplotypes (SNPs) alter specific aspects of the activation and regulation of the complement cascade, providing valuable insights into the pathogenic mechanisms of AMD with important diagnostic and therapeutic implications. The effect of targeting these AMD-related SNPs on the regulation of the complement cascade has been poorly explored, and the CRISPR/Cas system provides an ideal tool with which to explore this avenue. Current research concentrates on the association events of specific AMD-related SNPs in complement genes without looking into the effect of targeting these SNPs and therefore influencing the complement system in AMD pathogenesis. This review will explore the current understanding of manipulating the complement system in AMD pathogenesis utilising the genomic manipulation powers of the CRISPR/Cas systems. A number of AMD-related SNPs in different complement factor genes will be explored, with a particular emphasis on factor H (CFH), factor B (CFB), and complement C3 (C3).
Related Concept Videos
iPS Cell Differentiation
CRISPR
Homologous Recombination

